Literature DB >> 922747

Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer.

W A Knight, R B Livingston, E J Gregory, W L McGuire.   

Abstract

The usefulness of estrogen receptor measurements in primary breast tumors in the prediction of early recurrence was examined in a series of 145 patients. The absence of estrogen receptor in such tumors was associated with early recurrence independent of other known prognostic factors such as axillary lymph node status and tumor size.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 922747

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  151 in total

Review 1.  Intrinsic and Extrinsic Factors Governing the Transcriptional Regulation of ESR1.

Authors:  David K Lung; Rebecca M Reese; Elaine T Alarid
Journal:  Horm Cancer       Date:  2020-06-26       Impact factor: 3.869

2.  Prognostic and Predictive Factors for Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1995-10-31       Impact factor: 4.239

3.  Analysis of estrogen receptor messenger RNA in breast carcinomas from archival specimens is predictive of tumor biology.

Authors:  C Carmeci; E C deConinck; T Lawton; D A Bloch; R J Weigel
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

4.  Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer.

Authors:  Sidra Nawaz; Andreas Heindl; Konrad Koelble; Yinyin Yuan
Journal:  Mod Pathol       Date:  2015-02-27       Impact factor: 7.842

5.  Comparison of extent of disease and morphometric and DNA flow cytometric prognostic factors in invasive ductal breast cancer.

Authors:  A M Uyterlinde; N W Schipper; J P Baak
Journal:  J Clin Pathol       Date:  1987-12       Impact factor: 3.411

6.  Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up.

Authors:  J M Raemaekers; L V Beex; A J Koenders; G F Pieters; A G Smals; T J Benraad; P W Kloppenborg
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

7.  Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.

Authors:  Mohamed Ismail Nounou; Chris E Adkins; Evelina Rubinchik; Tori B Terrell-Hall; Mohamed Afroz; Tim Vitalis; Reinhard Gabathuler; Mei Mei Tian; Paul R Lockman
Journal:  Pharm Res       Date:  2016-08-15       Impact factor: 4.200

8.  MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype.

Authors:  D K Ways; C A Kukoly; J deVente; J L Hooker; W O Bryant; K J Posekany; D J Fletcher; P P Cook; P J Parker
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  An immunohistological study of breast cancer--with special reference to the expression of carbohydrate antigens and estrogen receptor status.

Authors:  M Sowa; Y S Chung; Y Kato; M Nishimura; T Kubo; H Maekawa; Y Fujimoto; K Umeyama; M Kawahara
Journal:  Jpn J Surg       Date:  1990-05

10.  Significance of the Tritiated Thymidine Labeling Index in breast cancers.

Authors:  K Araki; M Kimura; K Sakamoto; R Nishimura; M Akagi
Journal:  Jpn J Surg       Date:  1985-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.